Stephen Hoge Sells 40,294 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The shares were sold at an average price of $146.07, for a total value of $5,883,845.67.

Moderna Price Performance

Shares of MRNA traded up $1.85 during midday trading on Wednesday, reaching $145.62. The stock had a trading volume of 8,795,681 shares, compared to its average volume of 11,582,703. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm’s 50 day moving average price is $94.93 and its 200-day moving average price is $68.18. The company has a market capitalization of $58.14 billion, a P/E ratio of -18.23 and a beta of 1.10.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted ($2.13) earnings per share. On average, analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Institutional Trading of Moderna

A number of hedge funds have recently bought and sold shares of MRNA. TD Waterhouse Canada Inc. raised its position in Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after buying an additional 85 shares during the period. Assetmark Inc. raised its holdings in shares of Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares in the last quarter. New Mexico Educational Retirement Board boosted its position in Moderna by 1.9% during the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after purchasing an additional 300 shares during the last quarter. IFP Advisors Inc boosted its position in Moderna by 5.4% during the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after purchasing an additional 348 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its stake in Moderna by 16.9% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after purchasing an additional 382 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a research note on Friday, August 28th. They issued a “hold” rating on the stock. Bank of America upgraded shares of Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 19th. Bradesco Corretora upgraded shares of Moderna to an “outperform” rating in a research report on Friday, August 28th. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday, August 25th. Finally, UBS Group set a $81.00 price objective on Moderna in a research report on Thursday, September 3rd. Seven equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $76.72.

About Moderna

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.